Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jun 16;14(9):101154. doi: 10.1016/j.tranon.2021.101154

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 The Authors. Published by Elsevier Inc.

This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

PMC Copyright notice

Fig 6 — The simvastatin-romidepsin combination inhibited bladder cancer growth in vivo. (A) A murine allograft model was established using MBT-2 cells. The vehicle group received intraperitoneal injections of dimethyl sulfoxide (DMSO) and the treatment groups received 15 mg/kg simvastatin or 0.5 mg/kg romidepsin or both. The injections of romidepsin were given twice per week and the injections of DMSO and simvastatin were given once a day for 15 days (5 days on, 2 days off). Mean ± SE, n = 5. *p = 0.0079 at day 15. (B) Changes in the body weight. Mean ± SD, n = 5. Note that there is no significant difference in the body weight among each group at day 15. N. S., not significant. (C) Hematoxylin eosin (HE) staining of the tumors. After 15 days of treatment, the animals were euthanized and the subcutaneous tumors were harvested and evaluated by microscopy using HE staining. (D) Western blotting for AMP-activated protein kinase (AMPK), acetylated histone, glucose-regulated protein (GRP) 78, and peroxisome proliferator-activated receptor (PPAR) γ. After 15 days of treatment, the animals were euthanized and the subcutaneous tumors were harvested, lysed, and subjected to western blotting. Actin was used for the loading control. Representative blots are shown. Box-plot graphs show the relative densities of bands normalized to actin. n = 5. *p = 0.0079. V, vehicle-treated mice; R, romidepsin-treated mice; S, simvastatin-treated mice; R + S, combination-treated mice.

Fig 6 — The simvastatin-romidepsin combination inhibited bladder cancer growth in vivo. (A) A murine allograft model was established using MBT-2 cells. The vehicle group received intraperitoneal injections of dimethyl sulfoxide (DMSO) and the treatment groups received 15 mg/kg simvastatin or 0.5 mg/kg romidepsin or both. The injections of romidepsin were given twice per week and the injections of DMSO and simvastatin were given once a day for 15 days (5 days on, 2 days off). Mean ± SE, n = 5. *p = 0.0079 at day 15. (B) Changes in the body weight. Mean ± SD, n = 5. Note that there is no significant difference in the body weight among each group at day 15. N. S., not significant. (C) Hematoxylin eosin (HE) staining of the tumors. After 15 days of treatment, the animals were euthanized and the subcutaneous tumors were harvested and evaluated by microscopy using HE staining. (D) Western blotting for AMP-activated protein kinase (AMPK), acetylated histone, glucose-regulated protein (GRP) 78, and peroxisome proliferator-activated receptor (PPAR) γ. After 15 days of treatment, the animals were euthanized and the subcutaneous tumors were harvested, lysed, and subjected to western blotting. Actin was used for the loading control. Representative blots are shown. Box-plot graphs show the relative densities of bands normalized to actin. n = 5. *p = 0.0079. V, vehicle-treated mice; R, romidepsin-treated mice; S, simvastatin-treated mice; R + S, combination-treated mice.